Moheb Costandi's profile photo

Moheb Costandi

London

Freelance Science Writer at Freelance

Neuroscientist/ freelance writer. Author of BODY AM I: THE NEW SCIENCE OF SELF-CONSCIOUSNESS https://t.co/zLBERRbfaY

Featured in: Favicon bbc.co.uk Favicon medium.com Favicon theguardian.com Favicon dailymail.co.uk Favicon elpais.com Favicon huffpost.com Favicon nature.com Favicon gizmodo.com Favicon mit.edu (+1) Favicon pbs.org

Articles

  • EULAR 2023 - Terapias regenerativas frente a células madre en la artrosis:¿promesa o hype?

    Jan 8, 2025 | univadis.es | Moheb Costandi

    Los avances en terapias regenerativas para la reparación del cartílago son esperanzadores, pero los tratamientos para la artrosis basados en células madre son en su mayor parte “pura palabrería”, según los líderes en este campo que describieron recientes investigaciones en el Congreso Europeo Anual de Reumatología ( EULAR) celebrado en Milán.

  • Los editores de revistas médicas se movilizan contra la amenaza de guerra nuclear

    Jan 8, 2025 | univadis.es | Moheb Costandi

    Un editorial publicado el pasado 1 de agosto simultáneamente en varias revistas ha instado a los profesionales sanitarios a hacer lo posible por reducir el riesgo de guerra nuclear y abolir las armas nucleares.

  • The new age of the cyborg?

    Dec 5, 2024 | newhumanist.org.uk | Moheb Costandi

    In May, Noland Arbaugh became the first recipient of a Neuralink brain-computer interface. The 29-year-old had suffered a spinal injury while swimming – an accident that left him paralysed from the neck down. For the last eight years he had been using a wheelchair and a stick held in his mouth to handle electronic devices. But now there’s another way. Brain-computer interfaces, or BCIs, can translate intended movement signals in the brain into computer commands.

  • El tratamiento sistémico puede reducir la necesidad de radioterapia cerebral

    Oct 10, 2024 | espanol.medscape.com | Moheb Costandi

    close ¿Está seguro que quiere cerrar su sesión? BARCELONA. El objetivo del oncólogo es proporcionar el tratamiento más eficaz y menos tóxico disponible a pacientes con cáncer.

  • TDXd Better Than Chemo for HER2-Low Breast Cancer?

    Oct 3, 2024 | medscape.com | Moheb Costandi

    BARCELONA, Spain — Trastuzumab deruxtecan (TDXd) shows promise as a treatment for HER2-low and HER2-ultralow hormone receptor (HR)–positive metastatic breast cancer, according to data from the DESTINY-Breast06 trial presented here at the European Society for Medical Oncology (ESMO) Annual Meeting 2024. This multicenter, randomized, phase 3 trial compared TDXd, an antibody-drug conjugate (ADC), with chemotherapy in 866 patients with HER2-low or HER2-ultralow HR–positive metastatic breast cancer.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Coverage map

X (formerly Twitter)

Followers
34K
Tweets
30K
DMs Open
No
Moheb Costandi
Moheb Costandi @mocost
11 Apr 25

Nature Outlook supplement about sleep https://t.co/NL8H6YGoNh

Moheb Costandi
Moheb Costandi @mocost
31 Mar 25

RT @MichaelOkun: Wouldn't it be cool to be able to stimulate deep within the brain without the need for brain surgery (i.e. DBS), and witho…

Moheb Costandi
Moheb Costandi @mocost
30 Mar 25

"Tool use by fish: the fish holds a hard-shelled prey item in its mouth and strikes it onto a hard surface (anvil) to open it" https://t.co/qPJKy31jNw https://t.co/7Hz3uy14nz